reports Archives - AudioMedica.com

Tagged: reports

- in News · Oncology
- — 26 Feb, 2008
Chronic Lymphocytic Leukemia After Fludarabine Failure

John Gribben
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as
…
Read more
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
…
Read more
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
…
Read more
- in Cardiovascular
- — 5 Nov, 2007
TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

Gordon Tomaselli

Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new
…
Read more
- in General Medicine
- — 21 Sep, 2007
BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns

Jennifer Lavrrar, Jane Hata, Jeanette Block
REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JANE HATA, bioMéríeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter
…
Read more
- in Oncology
- — 31 Aug, 2007
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

Pierre Laurent-Puig

Bill Hait
REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor
…
Read more
- in ASCO · Oncology
- — 5 Jun, 2007
ASCO Annual Meeting Daily News Podcasts – June 5th, 2007

Aimery de Gramont

Robert Mayer
MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer
REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT
…
Read more
- in ASCO · Oncology
- — 5 Jun, 2007
ASCO Annual Meeting Daily News Podcasts – June 4th, 2007

Josep Llovet

Robert Mayer
Sorafenib The ‘New Standard’ for Advanced Liver Cancer
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT
…
Read more